TMCnet News
Research and Markets: The Hepatitis C Market Forecast to 2022 - Revolutionary Interferon-Free Regimens ArriveDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/b28wl6/the_hepatitis_c) has announced the addition of the "The Hepatitis C Market Forecast to 2022" report to their offering. The hepatitis C market is set to experience a boom as revolutionary interferon-free regimens arrive. A patient-based approach utilizing epidemiology data, and primary research in physicians has been utilized to estimate the size of hepatitis C sales across the US, Japan, and five major EU markets. The sales trends of key marketed and pipeline brands and the anticipated shift in the treatment paradigm are assessed from 2013-2022. Features and benefits: - Excel and PDF with forecasts through to 2022 covering the US, Japan, and 5 major EU markets, to allow you to assess future growth opportunities - Sales trends of marketed and late-phase pipeline products with detailed analysis of how each one will be positioned in the growing hepatitis C market. - Gain insight into how treatment paradigms will change as interferon-free regimens deliver large improvements in efficacy, tolerability and duration. Highlights: <> - The launch of multiple regimens in quick succession will fuel rapid market growth, with a CAGR of 13.0%. To drive sales, companies must encourage the lucrative warehoused subgroup to initiate treatment, while exploring expansions into genotype 2/3/4 patients where competition is scarcer.- Gilead's sofosbuvir is a remarkable example of product positioning that developers must emulate. Its dominance will be aided by pan-genotypic indications and incorporation into cheaper dual regimens with best-of-class drugs. - As interferon-based therapies are phased out, companies must move towards developing tailored oral combinations of NS5A, NS5B, and protease inhibitors, or position their products as key components of such regimens. Your key questions answered: - How will the launch of novel regimens with high cure rates affect the size of the hepatitis C market over the next decade - How will treatment paradigms be affected by the launch of oral regimens - How will developers of interferon-based therapies reposition their products in response to Gilead's and AbbVie's combinations Key Topics Covered: EXECUTIVE SUMMARY MARKET OVERVIEW AND TRENDS - The hepatitis C market will experience a boom over the next decade - The US market will be boosted by high drug prices and a greater prevalence of infections - Japan's market growth will be stunted by falling patient numbers - Interferon-based therapies will be replaced with all-oral regimens - Collaborative trials will prolong product revenues - NS5B inhibitors will form the basis of oral combinations - Price will be the major determinant of uptake of combination regimens - New product launches will dominate the market METHODOLOGY AND MARKET DEFINITION Companies Mentioned - Roche - Merck & Co. - Johnson & Johnson - Gilead - Boehringer Ingelheim - Bristol-Myers Squibb For more information visit http://www.researchandmarkets.com/research/b28wl6/the_hepatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. |
